Vitamin D supplementation and muscle strength in sarcopenic and obese sarcopenic elderly Lebanese people
| ISRCTN | ISRCTN10618249 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10618249 |
| Secondary identifying numbers | 1.2 |
- Submission date
- 02/06/2017
- Registration date
- 06/06/2017
- Last edited
- 14/07/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims:
Sarcopenia is a condition associated with old age, which involves loss of muscle mass and strength. This can lead to problems with balance and movement, increasing the risk of falling and fractures in the elderly. Vitamin D is essential for good health, because it helps our bodies to absorb calcium from the diet. There is a lot of evidence that having enough vitamin D plays an important role in muscle and bone health. Although vitamins generally come from the diet, in the case of vitamin D, the majority of people actually get most of it from sunlight. Vitamin D deficiency or insufficiency is a common health problem in older adults. It has been found that obese older adults have low vitamin D levels and low muscle strength and mass (sarcopenic obesity). The aim of this study is to look at the effects of vitamin D supplementation on sarcopenic individuals and individuals with sarcopenic obesity.
Who can participate?
Adults aged 70 and over who are deficient in vitamin D.
What does the study involve?
Participants are randomly allocated to one of four groups. Those in the first and third group are obese and those in the second and fourth group are of normal weight. In each pair of groups, one group receives a weekly supplement of vitamin D for six months, and the other receives a weekly supplement containing a placebo (dummy pill) for six months. At the start of the study and then six months later, participants have a blood test to assess their vitamin D levels, as well as being weighed and taking parts in assessments of muscle strength and function.
What are the possible benefits and risks of participating?
Participants who receive the vitamin D may benefit from improved muscle strength and function. There is a small risk of pain or bruising when blood samples are collected.
Where is the study run from?
Saint Charles Hospital (Lebanon)
When is study starting and how long is it expected to run for?
April 2015 to September 2015
Who is funding the study?
Saint Charles Hospital (Lebanon)
Who is the main contact?
Ms Cynthia El Hajj
cynthiaeliashajj102@gmail.com
Contact information
Scientific
Hôpital St. Charles
Fiyadiyeh
Baabda
13008
France
| Phone | +33 601 465 473 |
|---|---|
| cynthiaeliashajj102@gmail.com |
Study information
| Study design | Interventional randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Other |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Effect of vitamin D supplementation on muscle mass and strength in sarcopenic and obese sarcopenic older Lebanese people |
| Study objectives | The aim of this study is to evaluate the effects of weekly supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) over 6 months on muscle strength and sarcopenia. Null hypothesis: Vitamin D supplementation will not have effect on muscle strength and sarcopenia of the participants. Alternative hypothesis: Vitamin D supplementation will increase muscle mass and decrease sarcopenia of the participants. |
| Ethics approval(s) | Committee Ethical Approval Form (CEAF) of Saint Charles Hospital, 11/05/2015, ref: 11/5 |
| Health condition(s) or problem(s) studied | Vitamin D deficiency |
| Intervention | Participants are randomised to one of four groups. Those in group one and three have a BMI over 30 and those in groups two and four have a BMI within the normal range. Group 1: Participants receive a weekly supplement of 10,000 IU cholecalciferol (vitamin D) for 6 months Group 2: Participants receive a weekly supplement of 10,000 IU cholecalciferol (vitamin D) for 6 months Group 3: Participants receive a weekly supplement of a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) for 6 months Group 4: Participants receive a weekly supplement of a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) for 6 months Follow up takes place after six months and involves phone calls every three months and assessment at baseline and after 6 months of supplementation. |
| Intervention type | Supplement |
| Primary outcome measure | All primary outcomes are assessed at baseline and after 6 months of intervention. 1. Vitamin D (25(OH)D) is measured by radioimmunoassay (DiaSorin, Stillwater, MN) 2. Handgrip strength is measured in the dominant hand with a Martin vigorimeter (Martin; Elmed, Addison, IL, USA), and the force was expressed in kilograms (kg) 3. Skeletal muscle mass is anticipated from bioimpedance analysis measurements (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) and expressed as appendicular skeletal muscle mass (ASMM, kg) 4. Total lean body mass is measured using Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA 5. Fat mass is measured using Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA 6. Parathyroid hormone is measured using a two-site immunoradiometric assay with an NH2-terminal monoclonal antibody as capture (Fitzgerald Industries International Inc., USA) |
| Secondary outcome measures | All secondary outcomes are assessed at baseline and after 6 months of intervention. 1. Weight (kg) is assessed using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois,USA) 2. Body mass index (BMI) is calculated using the standard formula (body weight in kilograms divided by the square of the body height in meters [kg/m²]) 3. Serum creatinine is measured using the Jaffe rate method, the kinetic alkaline picrate (Interpretation and Techniques, Lea and Febiger, Philadelphia) |
| Overall study start date | 06/04/2015 |
| Completion date | 30/09/2015 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Senior |
| Sex | Both |
| Target number of participants | 116 |
| Key inclusion criteria | 1. Deficient in vitamin D 2. Age 70 years and over 3. No medical history of type 2 diabetes, congestive heart failure, renal failure or acute heart insufficiency |
| Key exclusion criteria | 1. Not deficient in vitamin D 2. Under 70 years of age 3. Having a medical history of type 2 diabetes, congestive heart failure, renal failure or acute heart insufficiency |
| Date of first enrolment | 02/07/2015 |
| Date of final enrolment | 30/09/2015 |
Locations
Countries of recruitment
- France
- Lebanon
Study participating centre
Beirut
50
France
Sponsor information
Hospital/treatment centre
Fiyadiyeh
Baabda
-
Lebanon
| Phone | +961 5 45 11 00 |
|---|---|
| cynthiaeliashajj102@gmail.com |
Funders
Funder type
Hospital/treatment centre
No information available
Results and Publications
| Intention to publish date | 15/11/2017 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request from Cynthia El Hajj (cynthiaeliashajj102@gmail.com) |
Editorial Notes
14/07/2017: Intention to publish date has been added.
